ROS receptor tyrosine kinase: A new potential target for anticancer drugs

Medicinal Research Reviews

Volumn 31, Issue 5, 2011, Pages 794-818

  El Deeb, Ibrahim Mustafa ^a,b   Yoo, Kyung Ho ^a   Lee, So Ha ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

Cancer; Glioblastoma; NSCLC; Receptor tyrosine kinase; ROS

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 5 AZA 2' DEOXYCITIDINE; ANTINEOPLASTIC AGENT; AST 487; CD74 ANTIGEN; D 64406; HYBRID PROTEIN; KIST 301072; KIST 301080; MALE CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 2; PYRAZOLE DERIVATIVE; RIBONUCLEASE; RNA; ROS KINASE; ROS KINASE INHIBITOR; SMALL INTERFERING RNA; SODIUM PHOSPHATE COTRANSPORTER; SODIUM PHOSPHATE COTRANSPORTER 2B; STAT PROTEIN; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAV PROTEIN; ONCOPROTEIN; ROS1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BREAST FIBROADENOMA; CARDIOVASCULAR DISEASE; CHROMOSOME 6; CHROMOSOME TRANSLOCATION; COLON CANCER; DISEASE ASSOCIATION; DROSOPHILA MELANOGASTER; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FERTILIZATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; GLIOBLASTOMA; HEART INFARCTION; HUMAN; INFERTILITY; KIDNEY CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MENINGIOMA; NONHUMAN; ONCOGENE; ONCOGENE C ROS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; MUTATION; NEOPLASMS; PHYSIOLOGY; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; INFERTILITY; MUTATION; NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 80052055991     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20206     Document Type: Review

References (150)

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-5557.
2. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411:355-365.
3. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome positive leukemias. New Engl J Med 1988;319:990-998.
4. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: Clinical value of their detection by immunocytochemistry. Blood 2002;99:409-426.
5. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
6. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009;1795:37-52.
7. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH. Design, synthesis and biological evaluation of new potent and highly selective ROS-tyrosine kinase inhibitor. Bioorg Med Chem Lett 2009;19:4720-4723.
8. El-Deeb IM, Park BS, Jung SJ, Yoo KH, Oh CH, Cho SJ, Han DK, Lee JY, Lee SH. Design, synthesis, screening, and molecular modeling study of a new series of ROS receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2009;19:5622-5626.
9. Balduzzi PC, Notter MFD, Morgan HR, Shibuya M. Some biological properties of two new avian sarcoma viruses. J Virol 1981;40:268-275.
10. Shibuya M, Hanafusa H, Balduzzi PC. Cellular sequences related to three new onc genes of avian sarcoma virus (fps, yes, and ROS) and their expression in normal and transformed cells. J Virol 1982;42:143-152.
11. Wang LH, Hanafusa H, Notter, MF, Balduzzi, PC. Genetic structure and transforming sequence of avian sarcoma virus UR2. J Virol 1982;41:833-841.
12. Neckameyer WS, Shibuya M, Hsu MT, Wang LH. Proto-oncogene c-ROS codes for a molecule with structural features common to those of growth factor receptors and displays tissue-specific and developmentally regulated expression. Mol Cell Biol 1986;6:1478-1486.
13. Matsushime H, Wang LH, Shibuya M. Human c-ROS gene homologous to the v-ROS sequence of UR2 sarcoma virus encodes for a transmembrane receptor-like molecule. Mol Cell Biol 1986;6:3000-3004.
14. Feldman RA, Wang LH, Hanafusa H, Balduzzi PC. Avian sarcoma virus UR2 encodes a transforming protein which is associated with a unique protein kinase activity. J Virol 1982;42:228-236.
15. Neckameyer WS, Wang LH. Nucleotide sequence of avian sarcoma virus UR2 and comparison of its transforming gene with other members of the tyrosine protein kinase oncogene family. J Virol 1985;53:879-884.
16. Ullich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985;313:756-761.
17. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullich A, Schlessinger J, Waterfield MD. Close similarity of epidermal growth factor receptor and v-erbB on oncogene protein sequences. Nature 1984;307:521-527.
18. Ebina Y, Ellins L, Jarnagin K, Edery M, Graf L, Clauser E, Ou J, Masiarz F, Kan YW, Goldfine ID, Roth RA, Rutter WJ. The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling. Cell 1985;40:747-758.
19. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look TA, Stanly RE. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985;41:665-676.
20. Matsushime H, Shibuya M. Tissue-specific expression of rat c-ROS-1 gene and partial structural similarity of its predicted products with sev protein of Drosophila melanogaster. J Virol 1990;64:2117-2125.
21. Birchmeier C, O'Neill K, Riggs M, Wigler M. Characterization of ROS cDNA from a human glioblastoma cell line. Proc Natl Acad Sci USA 1990;87:4799-4803.
22. Basler K, Hafen E. Control of photoreceptor cell fate by the sevenless protein requires a functional tyrosine kinase domain. Cell 1988;54:299-311.
23. Bowtell D, Simon M, Rubin G. Nucleotide sequence and structure of the sevenless gene of Drosophila melanogaster. Genes Dev 1988;2:620-634.
24. Bishop JM. Viral Oncogenes. Cell 1985;42:23-28.
25. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlesinger J, Downward J, Mayes E, Whittle N, Waterfield M, Seeburg PH. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-425.
26. Sonnenberg E, Godecke A, Walter B, Bladt F, Birchmeier C. Transient and locally restricted expression of the ROS proto-oncogene during mouse development. EMBO J 1991;10:3693-3702.
27. Sonnenberg-Riethmacher E, Walter B, Riethmacher D, Godecke S, Birchmeier C. The c-ROS tyrosie kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. Genes Dev 1996;10:1184-1193.
28. Liu ZZ, Wada J, Kumar A, Carone FA, Takahashi M, Kanwar YS. Comparative role of phosphotyrosine kinase domains of c-ROS and c-ret proto-oncogenes in metanephric development with respect to growth factors and matrix morphogens. Dev Biol 1996;178:133-148.
29. Chen J, Zong CS, Wang LH. Tissue and epithelial cell-specific expression of chicken proto-oncogene c-ROS in several organs suggests that it may play roles in their development and mature functions. Oncogene 1994;9:773-780.
30. Légaré C, Sullivan R. Expression and localization of c-ROS oncogene along the human excurrent duct. Mol Hum Reprod 2004;10:697-703.
31. Doolittle RF, Hunkapiller MW, Hood LE, Devare SG, Robbins KC, Aaronson SA, Antoniades HN. Simian sarcoma virus onc gene, v-sis, is derived from the gene or (genes) encoding a platelet-derived growth factor. Science 1983;222:275-277.
32. Waterfield MD, Scrace ST, Whittle N, Stroobant P, Johnson A, Wasteson A, Westermark B, Heldin CH, Huang JS, Deuel TF. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983;304:35-39.
33. Nagarajan L, Louie E, Tsujimoto Y, Balduzzi PC, Huebner K, Croce CM. The human c-ROS gene (ROS) is located at chromosome region 6q16→6q22. Proc Natl Acad Sci USA 1986;83:6568-6572.
34. Mitelman F. Chromosome 6. Cytogenet Cell Genet 1983;36:105-123.
35. Trent JM, Rosenfeld SB, Meyskens FL. Chromosome 6q involvement in human malignant melanoma. Cancer Genet Cytogenet 1983;9:177-180.
36. Atkin NB, Baker MC. Specific chromosome change in ovarian cancer. Cancer Genet Cytogenet 1981;3:275-276.
37. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-8022.
38. Libermann TA, Nussbaum HR, Razon N, Kris R, Lax I, Soreq M, Whittle N, Waterfield MD, Ullrich A, Schlessinger J. Amplification, enhanced expression and possible rearrangement of the EGF-receptor in primary human brain tumors of glial origin. Nature 1985;313:144-147.
39. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987;84:6899-6903.
40. Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S, Shibuya M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 1988;8:1816-1820.
41. Bernstein JJ, Anagnostopoulos AV, Hattwick EA, Laws ER. J. Human-specific c-neu proto-oncogene protein overexpression in human malignant astrocytomas before and after xenografting. J Neurosurg 1993;78:240-251.
42. Gillaspy GE, Mapstone TB, Samols D, Goldthwait DA. Transcriptional patterns of growth factors and proto-oncogenes in human glioblastomas and normal glial cells. Cancer Lett 1992;65:55-60.
43. Hayes C, Kelly D, Murayama S, Komiyama A, Suzuki K, Popko B. Expression of the neu oncogene under the transcriptional control of the myelin basic protein gene in transgenic mice: Generation of transformed glial cells. J Neurosci Res 1992;31:175-187.
44. La Rocca RV, Rosenblum M, Westermark B, Israel MA. Patterns of proto-oncogene expression in human glioma cell lines. J Neurosci Res 1989;24:97-106.
45. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992;52:3213-3219.
46. Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH, Schlessinger J, Westermark B. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 1988;48:3910-3918.
47. Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991;226:16755-16763.
48. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells. Cancer Res 2002;62:3729-3735.
49. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS gene in human glioblastoma cells. Proc Natl Acad Sci USA 1987;84:9270-9274.
50. Mapstone T, McMichael M, Goldthwait D. Expression of platelet-derived growth factors, transforming growth factors, and the ROS gene in a variety of primary human brain tumors. Neurosurgery 1991;28:216-222.
51. Watkins D, Dion F, Poisson M, Delattre JY, Rouleau GA. Analysis of onocogen expression in primary human gliomas: Evidence for increased expression of the ROS onocogene. Cancer Genet Cytogenet 1994;72:130-136.
52. Jun HJ, Woolfenden S, Coven S, Lane K, Bronson R, Housman D, Charest A. Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer Res 2009;69:2180-2184.
53. Wu JK, Chikaraishi DM. Differential expression of ROS oncogene in primary human astrocytomas and astrocytoma cell lines. Cancer Res 1990;50:3032-3035.
54. Zhao JF, Sharma S. Expression of the ROS oncogene for tyrosine receptor kinase in adult human meningiomas. Cancer Genet Cytogenet 1995;83:148-154.
55. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes, M, Sullivan L, Mitchell J, Wetzel R, MacNeill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
56. Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 2006;66:7473-7481.
57. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
58. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357.
59. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, Petersen I. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-13789.
60. Bonner AE, Lemon WJ, Devereux TR, Lubet RA, You M. Molecular profiling of mouse lung tumors: Association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene 2004;23:1166-1176.
61. Yamashita S, Nomoto T, Abe M, Tatematsu M, Sugimura T, Ushijima T. Persistence of gene expression changes in stomach mucosae induced by short-term N-methyl-N'-nitro-N-nitrosoguanidine treatment and their presence in stomach cancers. Mutat Res 2004;549:185-193.
62. Eom M, Han A, Yi SY, Shin JJ, Cui Y, Park KH. RHEB expression in fibroadenomas of the breast. Pathol Int 2008;58:226-232.
63. Yovchev MI, Grozdanov PN, Joseph B, Gupta S, Dabeva MD. Novel hepatic progenitor cell surface markers in the adult rat liver. Hepatology 2007;45:139-149.
64. Yovchev MI, Grozdanov PN, Zhou H, Racherla H, Guha C, Dabeva MD. Identification of adult hepatic progenitor cells capable of repopulating injured rat liver. Hepatology 2008;47:636-647.
65. Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P, Knyazeva T, Tay LS, Loo HL, Foo P, Wong W, Pok S, Lim SJ, Ong H, Luo M, Ho HK, Peng K, Lee TC, Bezler M, Mann C, Gaertner S, Hoefler H, Iacobelli S, Peter S, Tay A, Brenner S, Venkatesh B, Ullrich A. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 2007;67:11368-11376.
66. Zong CS, Poon B, Chen J, Wang LH. Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ROS. J Virol 1993;67:6453-6462.
67. Zong CS, Wang LH. Modulatory effect of the transmembrane domain of the protein-tyrosine kinase encoded by oncogene ROS: Biological function and substrate interaction. Proc Natl Acad Sci USA 1994;91:10982-10986.
68. Fasano O, Birnbaum D, Edlund L, Fogh J, Wigler M. New human transforming genes detected by a tumorigenicity assay. Mol Cell Biol 1984:4;1695-1705.
69. Birchmeier C, Birnbaum D, Waitches G, Fasano O, Wigler M. Characterization of an activated human ROS gene. Mol Cell Biol 1986;6:3109-3116.
70. Sara VR, Prisell P, Sjogren B, Persson L, Boethius J, Enberg G. Enhancement of insulin-like growth factor 2 receptors in glioblastoma. Cancer Lett 1986;32:229-234.
71. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-4553.
72. Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 1992;89:4874-4878.
73. Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, James CD. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503.
74. Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, Housman D. Oncogenic targeting of an activated tyrosine kinase to the golgi apparatus in a glioblastoma. Proc Natl Acad Sci USA 2003;100:916-921.
75. Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, Housman D. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 2003;37:58-71.
76. Charest A, Lane K, McMahon K, Housman DE. Association of a novel PDZ domain-containing peripheral golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6. J Biol Chem 2001;276:29456-29465.
77. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968;74:465-486.
78. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP. Chromosome 19 translocation, overexpression of notch3, and human lung cancer. J Natl Can Inst 2000;92:1355-1357.
79. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007;448:561-566.
80. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernández PL, Ramirez J, Chan JKC, Grigioni WF, Campo E, Pileri SA, Falini B. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174:661-670.
81. Ailan G, Anthony P. A translocation leading to a fusion protein of a ROS kinase and a sodium phosphate transporter in human non-small cell lung carcinoma. PCT Int Appl 2007, WO 2007084631 A2.
82. Ting-Lei G, Ailan G. A translocation leading to formation of a ROS kinase fusion protein with CD74 associated with human non-small cell lung carcinoma. PCT Int Appl 2009, WO 2009051846 A2.
83. Murer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch 2004;447:763-767.
84. Rangel LB, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, Morin PJ. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene 2003;22:7225-7232.
85. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-1476.
86. Badve S, Deshpande C, Hua Z, Logdberg L. Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus. J Histochem Cytochem 2002;50:473-482.
87. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
88. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic Drugs. Curr Cancer Drug Targets 2006;6:107-121.
89. Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 2007;7:91-107.
90. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006;65:1181-1188.
91. Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH. Stat3 plays an important role in oncogenic ROS- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem 1998;273:28065-28072.
92. Wilson R, Ainscough R, Anderson K, Baynes C, Berks M, Bonfield J, Burton J, Connell M, Copsey T, Cooper J, Coulson A, Craxton M, Dear S, Du Z, Durbin R, Favello A, Fraser A, Fulton L, Gardner A, Green P, Hawkins T, Hillier L, Jier M, Johnston L, Jones M, Kershaw J, Kirsten J, Laisster N, Latreille P, Lightning J, Lloyd C, Mortimore B, O'Callaghan M, Parsons J, Percy C, Rifken L, Roopra A, Saunders D, Showedkeen R, Sims M, Smaldon N, Smith A, Smith M, Sonnhammer E, Staden R, Sulston J, Thierry-Mieg J, Thomas K, Vaudin M, Vaughan K, Waterston R, Watson A, Weinstock A, Wilkinson-Sproat J, Wohldman P. 2.2Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature 1994;368:32-38.
93. Henske EP, Short MP, Jozwiak S, Bovey CM, Ramlakhan S, Haines JL, Kwiatkowski DJ. Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Ann Hum Genet 1995;59:25-37.
94. Teramoto H, Salem P, Robbins KC, Bustelo XR, Gutkind JS. Tyrosine phosphorylation of the vav proto-oncogene product links FcRI to the Rac1-JNK pathway. J Biol Chem 1997;272:10751-10755.
95. Bustelo XR. The VAV family of signal transduction molecules. Crit Rev Oncog 1996;7:65-88.
96. Bustelo XR. Regulatory and signaling properties of the VAV family. Mol Cell Biol 2000;20:1461-1477.
97. Movilla N, Bustelo XR. Biological and regulatory properties of VAV-3, a new member of the VAV family of oncoproteins. Mol Cell Biol 1999;19:7870-7885.
98. Trenkle T, McClelland M, Adlkofer K, Welsh J. Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. Gene 2000;245:139-149.
99. Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M, Welsh J, Wang LH. VAV3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol 2000;20:9212-9224.
100. Nguyen KT, Zong CS, Uttamsingh S, Sachdev P, Bhanot M, Le MT, Chan JL, Wang LH. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in ROS-induced cell transformation. J Biol Chem 2002;277:11107-11115.
101. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009;9:237-249.
102. Fulda S. The PI3K/Akt/mTOR Pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 2009;9:729-737.
103. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.
104. de Souza PL, Russell PJ, Kearsley J. Role of the Akt pathway in prostate cancer. Curr Cancer Drug Targets 2009;9:163-175.
105. Uttamsingh S, Zong CS, Wang LH. Matrix-independent activation of phosphatidyl-inositol 3-kinase, Stat3, and cyclin A-associated Cdk2 is essential for anchorage-independent growth of v-ROS-transformed chicken embryo fibroblasts. J Biol Chem 2003;278:18798-18810.
106. Zong CC, Chan JL, Yang SK, Wang LH. Mutations of ROS differentially effecting signal transduction pathways leading to cell growth versus transformation. J Biol Chem 1997;272:1500-1506.
107. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (m-TOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 2004;8:621-635.
108. Shen SH, Bastien L, Posner BI, Chretien P. A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature 1991;352:736-739.
109. Wang N, Li Z, Ding R, Frank GD, Senbonmatsu T, Landon EJ, Inagami T, Zhao ZJ. Antagonism or synergism: Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J Biol Chem 2006;281:21878-21883.
110. Shultz LD, Coman DR, Bailey CL, Beamer WG, Sidman CL. "Viable motheaten," a new allele at the motheaten locus. I. Pathology. Am J Pathol 1984;116:179-192.
111. Keilhack H, Müller M, Böhmer SA, Frank C, Weidner KM, Birchmeier W, Ligensa T, Berndt A, Kosmehl H, Günther B, Müller T, Birchmeier C, Böhmer FD. Negative regulation of ROS receptor tyrosine kinase signaling: An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1. J Cell Biol 2001;152:325-334.
112. Biskup C, Böhmer A, Pusch R, Kelbauskas L, Gorshokov A, Majoul I, Lindenau J, Benndorf K, Böhmer FD. Visualization of SHP-1-target interaction. J Cell Sci 2004;117:5165-5178.
113. Imhof D, Nothmann D, Zoda MS, Hampel K, Wegert J, Bohmer FD, Reissmann S. Synthesis of linear and cyclic phosphopeptides as ligands for the N-terminal SH2-domain of protein tyrosine phosphatase SHP-1. J Pept Sci 2005;11:390-400.
114. Imhof D, Wieligmann K, Hampel K, Nothmann D, Zoda MS, Schmidt-Arras D, Zacharias M, Bhmer FD, Reissmann S. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain. J Med Chem 2005;48:1528-1539.
115. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004;103:2325-2331.
116. Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Arico, M, Masera G, Basso G, Sorcini M, Gelb BD, Biondi A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004;104:307-313.
117. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Curr Opin Hematol 2004;11:44-50.
118. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004;64:8816-8820.
119. Noguchi T, Matozaki T, Horita K, Fujioka Y, Kasuga M. Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin stimulated Ras activation. Mol Cell Biol 1994;14:6674-6682.
120. Saxton TM, Ciruna BG, Holmyard D, Kulkarni S, Harpal K, Rossant J, Pawson T. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat Genet 2000;24:420-423.
121. Zhan Y, O'Rourke DM. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res 2004;64:8292-8298.
122. Shiffman D, Ellis SG, Rowland CM, Malloy MJ, Luke MM, Iakoubova OA, Pullinger CR, Cassano J, Aouizerat BE, Fenwick RG, Reitz RE, Catanese JJ, Leong DU, Zellner C, Sninsky JJ, Topol EJ, Devlin JJ, Kane JP. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 2005;77:596-605.
123. Zee RYL, Michaud SE, Hengener HH, Diehl KA, Ridker PM. A prospective replication study of five gene variants previously associated with risk of myocardial infarction. J Thromb Haemost 2006;4:2093-2095.
124. Horne BD, Carlquist JF, Muhlestein JB, Nicholas ZP, Anderson JL. Associations with myocardial infarction of six polymorphisms selected from a three-stage genome-wide association study. Am Heart J 2007;154:969-975.
125. Koch W, Hoppmann P, Schömig A, Kastrati A. Variations of specific non-candidate genes and risk of myocardial infarction: A replication study. Int J Cardiol 2009, in press.
126. Oguri M, Kato K, Hibino T, Yokoi K, Segawa T, Matsuo H, Watanabe S, Nozawa Y, Murohara T, Yamada Y. Genetic risk for restenosis after coronary stenting. Atherosclerosis 2007;194:172-178.
127. Yamada Y, Kato K, Yoshida T, Yokoi K, Matsuo H, Watanabe S, Ichihara S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Yasunaga A, Park H, Tanaka M, Nozawa Y. Association of polymorphisms of ABCA1 and ROS with hypertension in Japanese individuals. Int J Mol Med 2008;21:83-89.
128. Yamada Y, Kato K, Oguri M, Yoshida T, Yokoi K, Watanabe S, Metoki N, Yoshida H, Satoh K, Ichihara S, Aoyagi Y, Yasunaga A, Park H, Tanaka M, Nozawa, Y. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 2008;21:801-808.
129. Yamada Y, Metoki N, Yoshida H, Satoh K, Kato K, Hibino T, Yokoi K, Watanabe S, Ichihara S, Aoyagi Y, Yasunaga A, Park H, Tanaka M, Nozawa Y. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke 2008;9:2211-2218.
130. Yeung CH, Sonnenberg-Riethmacher E, Cooper TG. Infertile spermatozoa of c-ROS tyrosine kinase receptor knockout mice show flagellar angulation and maturational defects in cell volume regulatory mechanisms. Biol Reprod 1999;61:1062-1069.
131. Yeung CH, Wagenfeld A, Nieschlag E, Cooper TG. The cause of infertility of male c-ROS tyrosine kinase receptor knockout mice. Biol Reprod 2000;63:612-618.
132. Smith TT, Yanagimachi R. The viability of hamster spermatozoa stored in the isthmus of the oviduct: The importance of sperm-epithelium contact for sperm survival. Biol Reprod 1990;42:450-457.
133. Smith TT, Yanagimachi R. Attachment and release of spermatozoa from the caudal isthmus of the hamster oviduct. J Reprod Fertil 1991;91:567-573.
134. Demott RP, Lefebvre R, Suarez SS. Carbohydrates mediate the adherence of hamster sperm to oviductal epithelium. Biol Reprod 1995;52:1395-1403.
135. Lefebvre R, Suarez SS. Effect of capacitation on bull sperm binding to homologous oviductal epithelium. Biol Reprod 1996;54:575-582.
136. Esponda P, Moreno M. Acrosomal status of mouse spermatozoa in the oviductal isthmus. J Exp Zool 1998;282:360-366.
137. Smith TT. The modulation of sperm function by the oviductal epithelium. Biol Reprod 1998;58:1102-1104.
138. Yeung CH, Anapolski M, Cooper TG. Measurement of volume changes in mouse spermatozoa using an electronic sizing analyzer and a flow cytometer: Validation and application to an infertile mouse model. J Androl 2002;23:522-528.
139. Yeung CH, Anapolski M, Sipila P, Wagenfeld A, Poutanen M, Huhtaniemi I, Nieschlag E, Cooper TG. Sperm volume regulation: Maturational changes in fertile and infertile transgenic mice and association with kinematics and tail angulation. Biol Reprod 2002;67:269-275.
140. Wagenfeld A, Yeung CH, Lehnert W, Nieschlag E, Cooper TG. Lack of glutamate transporter EAAC1 in the epididymis of infertile c-ROS receptor tyrosine kinase-deficient mice. J Androl 2002;23:772-782.
141. +-ATPase. Mol Reprod Dev 2004;68:159-168.
142. Yeung CH, Anapolski M, Setiawan I, Lang F, Cooper TG. Effects of putative epididymal osmolytes on sperm volume regulation of fertile and infertile c-ROS transgenic mice. J Androl 2004;25:216-223.
143. Banerjee P. Recognition of c-ROS oncogene inhibition with a FRET-based receptor construct. MURJ 2004;10:52-57.
144. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri1 P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-132.
145. Reaction Biology Corporation web site.
146. Glienke W, Maute L, Koehl U, Esser R, Milz E, Bergmann L. Effective treatment of leukemic cell lines with wt1 siRNA. Leukemia 2007;21:2164-2170.
147. Wang H, Tan SS, Wang XY, Liu DH, Yu CS, Bai ZL, He DL, Zhao J. Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells. Acta Pharmacol Sin 2007;28:1968-1974.
148. D'Astolfo DS, Gehrau RC, Bocco JL, Koritschoner NP. Silencing of the transcription factor KLF6 by siRNA leads to cell cycle arrest and sensitizes cells to apoptosis induced by DNA damage. Cell Death Differ 2008;15:613-616.
149. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 2008;16:942-946.
150. Gonzalez-Gonzalez E, Ra H, Hickerson RP, Wang Q, Piyawattanametha W, Mandella MJ, Kino GS, Leake D, Avilion AA, Solgaard O, Doyle TC, Contag CH, Kaspar RL. siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. Gene Ther 2009;16:963-972.